To the Editor: Dr Mangano and colleagues1 investigated the potential long-term effects of aprotinin use following CABG surgery. It appears that 2 important determinants of long-term CABG outcomes were not included in these analyses.

First, the extent of underlying coronary disease (1-, 2- or 3-vessel coronary disease; presence or absence of left main trunk disease) was not discussed.